Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Prostate Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Solid Tumor (16929
)
Lung Cancer (4108
)
Breast Cancer (2430
)
Colorectal Cancer (1365
)
Melanoma (1043
)
Sarcoma (668
)
Bladder Cancer (180
)
Solid Tumor (16929
)
Lung Cancer (4108
)
Breast Cancer (2430
)
Colorectal Cancer (1365
)
Melanoma (1043
)
Sarcoma (668
)
Bladder Cancer (180
)
›
Associations
(495)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
apalutamide
Sensitive
:
A1
apalutamide
Sensitive: A1 - Approval
apalutamide
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
histrelin acetate
Sensitive: A1 - Approval
histrelin acetate
Sensitive
:
A1
histrelin acetate
Sensitive: A1 - Approval
histrelin acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
cabazitaxel
Sensitive: A1 - Approval
cabazitaxel
Sensitive
:
A1
cabazitaxel
Sensitive: A1 - Approval
cabazitaxel
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
enzalutamide
Sensitive: A1 - Approval
enzalutamide
Sensitive
:
A1
enzalutamide
Sensitive: A1 - Approval
enzalutamide
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
relugolix
Sensitive: A1 - Approval
relugolix
Sensitive
:
A1
relugolix
Sensitive: A1 - Approval
relugolix
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
docetaxel + prednisone
Sensitive: A1 - Approval
docetaxel + prednisone
Sensitive
:
A1
docetaxel + prednisone
Sensitive: A1 - Approval
docetaxel + prednisone
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
abiraterone acetate
Sensitive: A1 - Approval
abiraterone acetate
Sensitive
:
A1
abiraterone acetate
Sensitive: A1 - Approval
abiraterone acetate
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
degarelix
Sensitive: A1 - Approval
degarelix
Sensitive
:
A1
degarelix
Sensitive: A1 - Approval
degarelix
Sensitive
:
A1
ATM mutation
Prostate Cancer
ATM mutation
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
darolutamide
Sensitive: A1 - Approval
darolutamide
Sensitive
:
A1
darolutamide
Sensitive: A1 - Approval
darolutamide
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
docetaxel
Sensitive: A1 - Approval
docetaxel
Sensitive
:
A1
docetaxel
Sensitive: A1 - Approval
docetaxel
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
rucaparib
Sensitive: A1 - Approval
rucaparib
Sensitive
:
A1
HRD
Prostate Cancer
HRD
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
zoledronic acid
Sensitive: A1 - Approval
zoledronic acid
Sensitive
:
A1
zoledronic acid
Sensitive: A1 - Approval
zoledronic acid
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
goserelin acetate + flutamide
Sensitive: A1 - Approval
goserelin acetate + flutamide
Sensitive
:
A1
goserelin acetate + flutamide
Sensitive: A1 - Approval
goserelin acetate + flutamide
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
goserelin acetate
Sensitive: A1 - Approval
goserelin acetate
Sensitive
:
A1
goserelin acetate
Sensitive: A1 - Approval
goserelin acetate
Sensitive
:
A1
FOLH1 positive
Prostate Cancer
FOLH1 positive
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive: A1 - Approval
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
lutetium Lu 177 vipivotide tetraxetan
Sensitive: A1 - Approval
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
leuprolide 6-month depot
Sensitive: A1 - Approval
leuprolide 6-month depot
Sensitive
:
A1
leuprolide 6-month depot
Sensitive: A1 - Approval
leuprolide 6-month depot
Sensitive
:
A1
HRD
Prostate Cancer
HRD
Prostate Cancer
talazoparib + enzalutamide
Sensitive: A1 - Approval
talazoparib + enzalutamide
Sensitive
:
A1
talazoparib + enzalutamide
Sensitive: A1 - Approval
talazoparib + enzalutamide
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
olaparib
Sensitive: A1 - Approval
olaparib
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
abiraterone/niraparib
Sensitive: A1 - Approval
abiraterone / niraparib
Sensitive
:
A1
abiraterone/niraparib
Sensitive: A1 - Approval
abiraterone / niraparib
Sensitive
:
A1
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
abiraterone/niraparib
Sensitive: A1 - Approval
abiraterone / niraparib
Sensitive
:
A1
abiraterone/niraparib
Sensitive: A1 - Approval
abiraterone / niraparib
Sensitive
:
A1
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
leuprorelin depot
Sensitive: A1 - Approval
leuprorelin depot
Sensitive
:
A1
leuprorelin depot
Sensitive: A1 - Approval
leuprorelin depot
Sensitive
:
A1
BRCA1 mutation
Prostate Cancer
BRCA1 mutation
Prostate Cancer
niraparib
Sensitive: A2 - Guideline
niraparib
Sensitive
:
A2
niraparib
Sensitive: A2 - Guideline
niraparib
Sensitive
:
A2
BRCA2 mutation
Prostate Cancer
BRCA2 mutation
Prostate Cancer
niraparib
Sensitive: A2 - Guideline
niraparib
Sensitive
:
A2
niraparib
Sensitive: A2 - Guideline
niraparib
Sensitive
:
A2
MSI-H/dMMR
Prostate Cancer
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
mitoxantrone
Sensitive: A2 - Guideline
mitoxantrone
Sensitive
:
A2
mitoxantrone
Sensitive: A2 - Guideline
mitoxantrone
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
No biomarker
Prostate Cancer
No biomarker
Prostate Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login